ACEA Biosciences and Neural ID Announce Collaboration to Increase Throughput for More Predictive Preclinical Cardiac Liability Assays

Share Article

Alliance offers customers native integration of ACEA’s CardioECR platform with Neural ID’s biosignal analytics software to provide simultaneous cardiomyocyte contractility and field potential measurement and automated recognition, analysis and reporting of assay data.

“Researchers are keen to gain a deeper assessment of mechanism of toxicity and accelerate decision making around the safety and efficacy of new products,” said Timothy Carruthers, CEO, Neural ID.

Neural ID, the provider of the only enterprise biosignal analytics platform spanning the pharmaceutical research and development lifecycle, teams up with ACEA Biosciences for customer-focused collaboration to be launched during the Society of Toxicology (SOT) Annual Meeting March 22-26, 2015 in San Diego, CA.

The offering delivers a fully integrated solution by combining the recently released ACEA xCELLigence RTCA CardioECR System, a platform that delivers impedance and Multi Electrode Array (MEA) technology with a pacing function, with Neural ID’s flagship IWS software, which provides users with automated data analysis and reporting of key biosignals.

“Cardiovascular toxicity is consistently a leading cause of drug attrition and withdrawal. A number of drugs have been withdrawn from the market due to the risk of causing a potentially fatal form of ventricular arrhythmia referred to as Torsades de Pointes (TdP),” noted Yama Abassi, Ph.D., Vice President of ACEA Biosciences. “The RTCA CardioECR system provides a more predictive approach that can be used earlier in drug development to reduce both cost and risk. Integrating with Neural ID’s software to automate data analysis and reporting will further increase throughput and provide significant benefit to the pharmaceutical industry.”

“Researchers are keen to gain a deeper assessment of mechanism of toxicity and accelerate decision making around the safety and efficacy of new products. Combining the RTCA CardioECR system with Neural ID’s biosignal analytics software achieves both objectives,” said Timothy Carruthers, CEO, Neural ID. “We believe that it is also well aligned with the FDA CiPA initiative that seeks to develop a new paradigm for cardiac safety evaluation of new drugs.”

For more information on ACEA Biosciences and Neural ID, please visit booths 906 and 911 respectively at the SOT Meeting.

#####

About ACEA Biosciences

Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. Researchers are advancing their studies utilizing 1,500+ placed instruments for broad and diverse applications. The technology has been cited in over 600 peer reviewed publications. ACEA’s xCELLigence® impedance-based, label-free, real time cell analysis system and NovoCyte™ flow cytometers are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research. Further information is available at http://www.aceabio.com.

About Neural ID

Neural ID provides the only enterprise biosignal analytics platform spanning the pharmaceutical lifecycle. From discovery through clinical and health information, Neural ID delivers scalable collaborative solution addressing the industry’s productivity crisis. Our flagship product, Intelligent Waveform Solution (IWS) delivers expert-driven machine learning, massive data reduction and an interoperable data format to help customers make better decisions faster, leading to increased product revenues and reduced development costs. Neural ID, based in Redwood City, CA, launched IWS in 2013. Further information is available at http://www.neuralid.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jon Knisley
Neural ID
+1 703-665-9870
Email >
Visit website